keyword
MENU ▼
Read by QxMD icon Read
search

esophagogastric adenocarcinoma

keyword
https://www.readbyqxmd.com/read/28776577/pathologic-assessment-of-gastrointestinal-tract-and-pancreatic-carcinoma-after-neoadjuvant-therapy
#1
REVIEW
Reetesh K Pai, Rish K Pai
Neoadjuvant therapy is increasingly used to treat patients with a wide variety of malignancies. Histologic evaluation of treated specimens provides important prognostic information and may guide subsequent chemotherapy. Neoadjuvant therapy is commonly employed in the treatment of locally advanced rectal adenocarcinoma, hepatic colorectal metastases, esophageal/esophagogastric junction carcinoma, and pancreatic ductal adenocarcinoma. Numerous tumor regression schemes have been used in these tumors and standardized approaches to evaluate these specimens are needed...
August 4, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28765502/a-phase-ii-study-with-lead-in-safety-cohort-of-5-fluorouracil-oxaliplatin-and-lapatinib-in-combination-with-radiation-therapy-as-neoadjuvant-treatment-for-patients-with-localized-her2-positive-esophagogastric-adenocarcinomas
#2
Gregg Shepard, Edward R Arrowsmith, Patrick Murphy, John H Barton, James D Peyton, Mark Mainwaring, Laura Blakely, Noel A Maun, Johanna C Bendell
LESSONS LEARNED: Neoadjuvant 5-fluorouracil, oxaliplatin, and lapatinib in combination with radiation therapy is safe for neoadjuvant treatment for patients with localized human epidermal growth receptor 2-positive esophagogastric adenocarcinoma.Evaluation of this drug combination in a larger patient pool would allow for more accurate analysis of its efficacy. BACKGROUND: The optimal design of neoadjuvant chemoradiation for the treatment of localized esophagogastric cancers is the subject of much debate...
August 1, 2017: Oncologist
https://www.readbyqxmd.com/read/28760152/randomized-controlled-trial-of-s-1-maintenance-therapy%C3%A2-in-metastatic-esophagogastric-cancer-the-multinational-mateo-study
#3
Georg-Martin Haag, Gertraud Stocker, Julia Quidde, Dirk Jaeger, Florian Lordick
BACKGROUND: The optimal duration of firstline chemotherapy in metastatic esophagogastric cancer is unknown. In most clinical trials therapy was given until tumour progression or limiting toxicity. Maintenance concepts aiming to prolong the duration of response and maintain quality of life have been established in other tumour types but not in esophagogastric cancer. S-1 is an oral fluoropyrimidine with proven efficacy in metastatic esophagogastric cancer. METHODS: The Maintenance Teysuno® (S-1) in esophagogastric cancer (MATEO) trial is a multinational, randomized phase II study that explores the role of S-1 maintenance therapy in Her-2 negative, advanced esophagogastric adenocarcinoma...
July 31, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28747576/a-prospective-appraisal-of-preoperative-body-mass-index-in-d2-resected-patients-with-non-metastatic-gastric-carcinoma-and-siewert-type-ii-iii-adenocarcinoma-of-esophagogastric-junction-results-from-a-large-scale-cohort
#4
Lei Huang, Zhi-Jian Wei, Tuan-Jie Li, Yu-Ming Jiang, A-Man Xu
OBJECTIVE: To prospectively investigate associations of presurgical body mass index (BMI) with clinicopathological factors and its prognostic significance in radically D2-resected patients with non-metastasized gastric cancer (GC) and Siewert type II/III adenocarcinoma of esophagogastric junction (AEG). METHODS: A large prospective cohort consisting of radically-resected GC and AEG patients was analyzed. Follow-up was successful in 671 out of 700 patients, who were categorized into underweight (BMI<18...
July 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/28746229/the-prognostic-value-of-preoperative-inflammation-based-prognostic-scores-and-nutritional-status-for-overall-survival-in-resected-patients-with-nonmetastatic-siewert-type-ii-iii-adenocarcinoma-of-esophagogastric-junction
#5
Lixiang Zhang, Yezhou Su, Zhangming Chen, Zhijian Wei, Wenxiu Han, Aman Xu
BACKGROUND: Immune and nutritional status of patients have been reported to predict postoperative complications, recurrence, and prognosis of patients with cancer. Therefore, this retrospective study aimed to explore the prognostic value of preoperative inflammation-based prognostic scores [neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR)] and nutritional status [prognostic nutritional index (PNI), body mass index (BMI), hemoglobin, albumin, and prealbumin] for overall survival (OS) in adenocarcinoma of esophagogastric junction (AEG) patients...
July 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28741195/comparison-of-prognostic-abilities-among-preoperative-laboratory-data-indices-in-patients-with-resectable-gastric-and-esophagogastric-junction-adenocarcinoma
#6
Masayuki Urabe, Hiroharu Yamashita, Toshiaki Watanabe, Yasuyuki Seto
BACKGROUND: Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), modified Glasgow prognostic score (mGPS) and prognostic nutritional index (PNI) are simple indices determined employing laboratory data alone and have been used to predict the clinical outcomes of patients with esophagogastric tumors. However, prior results were generally based on analyzing dichotomous data with arbitrary cutoff values. This retrospective study aims to assess prognostic utilities of preoperative NLR, PLR, LMR, mGPS and PNI, as continuous variables, in gastric cancer (GC) and adenocarcinoma of esophagogastric junction (AEG)...
July 24, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/28741059/postoperative-follow-up-programs-improve-survival-in-curatively-resected-gastric-and-junctional-cancer-patients-a-propensity-score-matched-analysis
#7
Leila Sisic, Moritz J Strowitzki, Susanne Blank, Henrik Nienhueser, Sara Dorr, Georg Martin Haag, Dirk Jäger, Katja Ott, Markus W Büchler, Alexis Ulrich, Thomas Schmidt
BACKGROUND: To date there is no evidence that more intensive follow-up after surgery for esophagogastric adenocarcinoma translates into improved survival. This study aimed to evaluate the impact of standardized surveillance by a specialized center after resection on survival. METHODS: Data of 587 patients were analyzed who underwent curative surgery for esophagogastric adenocarcinoma in our institution. Based on their postoperative surveillance, patients were assigned to either standardized follow-up (SFU) by the National Center for Tumor Diseases (SFU group) or individual follow-up by other physicians (non-SFU group)...
July 24, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28740657/the-esophagogastric-junctional-adenocarcinoma-an-increasing-disease
#8
EDITORIAL
Monica Pastina, Cecilia Menna, Claudio Andreetti, Mohsen Ibrahim
No abstract text is available yet for this article.
June 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28736629/biologic-therapy-in-esophageal-and-gastric-malignancies-current-therapies-and-future-directions
#9
REVIEW
Pamela Samson, A Craig Lockhart
Biologic agents, including targeted antibodies as well as immunomodulators, are demonstrating unparalleled development and study across the entire spectrum of human malignancy. This review summarizes the current state of biologic therapies for esophageal, esophagogastric, and gastric malignancies, including those that target human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), c-Met, mechanistic target of rapamycin (mTOR) and immunomodulators...
June 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28685209/surgical-strategies-in-true-adenocarcinoma-of-the-esophagogastric-junction-aeg-ii-thoracoabdominal-or-abdominal-approach
#10
Susanne Blank, Thomas Schmidt, Patrick Heger, Moritz J Strowitzki, Leila Sisic, Ulrike Heger, Henrik Nienhueser, Georg Martin Haag, Thomas Bruckner, André L Mihaljevic, Katja Ott, Markus W Büchler, Alexis Ulrich
BACKGROUND: The optimal surgical approach for adenocarcinoma directly at the esophagogastric junction (AEG II) is still under debate. This study aims to evaluate the differences between right thoracoabdominal esophagectomy (TAE) (Ivor-Lewis operation) and transhiatal extended gastrectomy (THG) for AEG II. METHODS: From a prospective database, 242 patients with AEG II (TAE, n = 56; THG, n = 186) were included and analyzed according to characteristics and perioperative morbidity and mortality and overall survival (chi-square, Mann-Whitney U, log-rank, Cox regression)...
July 6, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28684226/the-postoperative-part-of-perioperative-chemotherapy-fails-to-provide-a-survival-benefit-in-completely-resected-esophagogastric-adenocarcinoma
#11
Leila Sisic, Susanne Blank, Henrik Nienhüser, Georg Martin Haag, Dirk Jäger, Tom Bruckner, Katja Ott, Thomas Schmidt, Alexis Ulrich
BACKGROUND: Based on two benchmark studies perioperative chemotherapy (CTx) has become standard treatment for locally advanced esophagogastric adenocarcinoma (EGA) in Europe. However, only half of the patients in both studies actually received postoperative CTx (aCTx). Thus, we evaluated the prognostic impact of preoperative CTx (nCTx) and aCTx combined versus nCTx alone. Furthermore, we aimed to identify subgroups potentially beneficial of aCTx and factors associated with its non-administration...
June 29, 2017: Surgical Oncology
https://www.readbyqxmd.com/read/28660324/-r1-resection-for-gastric-carcinoma
#12
REVIEW
K Ridwelski, J Fahlke, M Huß, R Otto, S Wolff
The results reported in the literature in the context of an R1 situation for a resected gastric carcinoma are not uniform. An R1 situation worsens the prognosis for the long-term survival of patients. This is significant especially for low T stages and lymph node metastasis with 0-≤3 lymph node metastases. In higher tumor stages with extensive lymph node metastases, the survival difference between R0 and R1 resections is lower and frequently no longer significant. The frequency of R1 resection is approximately 5% (range 1...
June 28, 2017: Der Chirurg; Zeitschrift Für Alle Gebiete der Operativen Medizen
https://www.readbyqxmd.com/read/28656339/short-term-outcomes-after-laparoscopic-versus-open-transhiatal-resection-of-siewert-type-ii-adenocarcinoma-of-the-esophagogastric-junction
#13
Shizuki Sugita, Takahiro Kinoshita, Akio Kaito, Masahiro Watanabe, Hideki Sunagawa
BACKGROUND: The potential advantages of laparoscopic surgery (LS) compared with open surgery (OS) for Siewert type II adenocarcinoma of the esophagogastric junction (AEG) have not been fully clarified. This study aimed to assess the feasibility and safety of the laparoscopic transhiatal approach for Siewert type II AEG, and compare the short-term outcomes of LS versus OS for Siewert type II AEG. METHODS: We retrospectively analyzed 87 consecutive patients with Siewert type II AEG who underwent curative surgery from January 2008 to November 2016...
June 27, 2017: Surgical Endoscopy
https://www.readbyqxmd.com/read/28637800/pharmacokinetics-biodistribution-and-radiation-dosimetry-for-89-zr-trastuzumab-in-patients-with-esophagogastric-cancer
#14
Joseph A O'Donoghue, Jason S Lewis, Neeta Pandit-Taskar, Stephen E Fleming, Heiko Schoder, Steven M Larson, Volkan Beylergil, Shutian Ruan, Serge Lyashchenko, Pat B Zanzonico, Wolfgang Andreas Weber, Jorge A Carrasquillo, Yelena Y Janjigian
Trastuzumab with chemotherapy improves clinical outcomes in patients with human epidermal growth factor receptor 2 (HER2)-positive esophagogastric adenocarcinoma (EGA). Despite the therapeutic benefit, responses are rarely complete and the majority of patients develop progression. This is the first report evaluating (89)Zr-trastuzumab in HER2-positive EGA in which we evaluate the safety, pharmacokinetics, biodistribution, and dosimetry. Methods: Trastuzumab was conjugated with deferoxamine and radiolabeled with (89)Zr...
June 21, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28628843/preoperative-chemotherapy-versus-chemoradiotherapy-in%C3%A2-locally-advanced-adenocarcinomas-of-the-oesophagogastric-junction-poet-long-term-results-of%C3%A2-a-controlled-randomised-trial
#15
Michael Stahl, Martin K Walz, Jorge Riera-Knorrenschild, Martin Stuschke, Andreas Sandermann, Michael Bitzer, Hansjochen Wilke, Wilfried Budach
BACKGROUND: Results of the PreOperative therapy in Esophagogastric adenocarcinoma Trial (POET) showed some benefits when including radiotherapy into the preoperative treatment. This article is reporting long-term results of this phase III study. PATIENTS AND METHODS: Patients with locally advanced adenocarcinomas of the oesophagogastric junction (Siewert types I-III) were eligible. Randomisation was done to chemotherapy (group A) or induction chemotherapy and chemoradiotherapy (CRT; group B) followed by surgery...
August 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28561677/immunotherapy-for-esophageal-and-gastric-cancer
#16
Ronan J Kelly
PD-L1 upregulation occurs in approximately 40% of gastroesophageal cancers. However, unlike other solid tumors, there is minimal PD-L1 expressed on the cancer cells; rather, expression occurs predominantly on infiltrating myeloid cells. Preliminary clinical data involving single-agent PD-1/PD-L1 inhibitors in metastatic gastroesophageal cancer have reported response rates of 22%-27% for patients with PD-L1(+) tumors and 10%-17% for unselected patients. The phase III ONO-4538-12 (ATTRACTION 2) trial has demonstrated an improved overall survival for nivolumab compared with placebo for patients with heavily pretreated gastric cancer...
2017: American Society of Clinical Oncology Educational Book
https://www.readbyqxmd.com/read/28556024/cancer-of-the-esophagus-and-esophagogastric-junction-major-changes-in-the-american-joint-committee-on-cancer-eighth-edition-cancer-staging-manual
#17
Thomas W Rice, Donna M Gress, Deepa T Patil, Wayne L Hofstetter, David P Kelsen, Eugene H Blackstone
Answer questions and earn CME/CNE New to the eighth edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual for epithelial cancers of the esophagus and esophagogastric junction are separate, temporally related cancer classifications: 1) before treatment decision (clinical); 2) after esophagectomy alone (pathologic); and 3) after preresection therapy followed by esophagectomy (postneoadjuvant pathologic). The addition of clinical and postneoadjuvant pathologic stage groupings was driven by a lack of correspondence of survival, and thus prognosis, between both clinical and postneoadjuvant pathologic cancer categories (facts about the cancer) and pathologic categories...
July 8, 2017: CA: a Cancer Journal for Clinicians
https://www.readbyqxmd.com/read/28551654/overexpression-of-egfr-as-an-independent-prognostic-factor-in-adenocarcinoma-of-the-esophagogastric-junction
#18
Kenichi Aratani, Shuhei Komatsu, Daisuke Ichikawa, Takuma Ohashi, Mahito Miyamae, Wataru Okajima, Taisuke Imamura, Jun Kiuchi, Keiji Nishibeppu, Toshiyuki Kosuga, Hirotaka Konishi, Atsushi Shiozaki, Hitoshi Fujiwara, Kazuma Okamoto, Hitoshi Tsuda, Eigo Otsuji
BACKGROUND: Adenocarcinoma of the esophagogastric junction (AEG) has increased in Western and Eastern countries, and its prognosis remains poor. We tested whether epidermal growth factor receptor (EGFR), that is overexpressed in various tumors, acts as a cancer-promoting gene through overexpression in AEG. MATERIALS AND METHODS: We analyzed 104 primary AEG tumors which were curatively resected in our hospital between 2000 and 2010. RESULTS: Overexpression of EGFR protein was detected in 47% primary AEG tumor samples, and significantly associated with venous and lymphatic invasion, tumor depth and lymph node metastasis...
June 2017: Anticancer Research
https://www.readbyqxmd.com/read/28529581/expression-of-serum-and-glucocorticoid-regulated-kinase-1-and-its-association-with-clinicopathological-factors-and-the-survival-of-patients-with-adenocarcinoma-of-the-esophagogastric-junction
#19
Shegan Gao, Dan Wang, Guoqiang Kong, Shuoguo Li, Wei Wang, Huizhi Wang, Fuyou Zhou
While the aberrant expression and the controversial results of serum- and glucocorticoid-regulated kinase (SGK1) have been reported in a number of malignancies, the expression of SGK1 and its possible association with the progression of adenocarcinoma in the esophagogastric junction (AEG) remain to be elucidated. To the best of our knowledge, the expression and localization of SGK1 was examined for the first time in the present study in cancerous and adjacent tissue from 60 patients with AEG, and compared with 20 healthy mucosa control tissue samples...
May 2017: Oncology Letters
https://www.readbyqxmd.com/read/28503799/lymph-node-dissection-for-siewert-ii-esophagogastric-junction-adenocarcinoma-a-retrospective-study-of-136-cases
#20
Xiaofeng Duan, Xiaobin Shang, Peng Tang, Hongjing Jiang, Zhentao Yu
BACKGROUND: To compare the lymph node dissection with the right transthoracic Ivor-Lewis (IL) procedure to that with the left transthoracic (LT) approach for Siewert type II adenocarcinoma of the esophagogastric (AEG) junction. METHODS: In this study, 136 patients with Siewert type II AEG who met the inclusion criteria underwent surgical resection were divided into the IL (47 cases) and LT (89 cases) groups. The number and frequency of the dissected lymph nodes in each station were compared between the two groups...
May 14, 2017: ANZ Journal of Surgery
keyword
keyword
105953
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"